+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia refractory to fludarabine



Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia refractory to fludarabine



Blood 94(10 SUPPL 1 PART 1): 705a, Nov 15




(PDF emailed within 1 workday: $29.90)

Accession: 035349922

Download citation: RISBibTeXText


Related references

Campath-1H in fludarabine-refractory chronic lymphocytic leukemia Results of a multicenter study. Cancer Investigation 18(SUPPL 1): 9-10, 2000

Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. Leukemia Research 38(1): 34-41, 2014

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia Research 39(5): 495-500, 2015

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99(6): 2245-2247, 2002

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leukemia & Lymphoma 52(10): 1936-1941, 2012

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leukemia & Lymphoma (): 1-8, 2016

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 26(2): 196-203, 2008

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 15(4): 1567-1574, 1997

Phase I study of rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 98(11 Part 1): 365a, November 16, 2001

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology 29(26): 3559-3566, 2011

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology 27(24): 3994-4001, 2009

Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia Results of a randomized phase-III multicenter Study. Blood 102(11): 437a, November 16, 2003

Successfull CD 34+ Priming with Intermediate Dose Ara-C in Chronic Lymphocytic Leukemia Patients Treated with Sequential Fludarabine and CAMPATH-1H. Blood 100(11): Abstract No 3277, November 16, 2002

Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia Preliminary results of a randomized phase-III multicenter study. Blood 96(11 Part 2): 294b, November 16, 2000

Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 87(7): 695-700; Discussion 700, 2002